Indications for Use: LumosityRx is a digital therapeutic indicated to improve attention function in adults ages 22-55 years old with primarily inattentive or combined-type Attention Deficit and Hyperactivity Disorder (ADHD). Patients who engage with LumosityRx demonstrate improvements in a digitally assessed measure of sustained and selective attention, Test of Variables of Attention (TOVA), and may not display benefits in typical behavioral symptoms, such as hyperactivity. LumosityRx should be considered for use as part of a therapeutic program that may include clinician directed therapy, medication, and/or educational programs, which further address symptoms of the disorder.
Improved Attention and Quality of Life
Results from our pivotal study with 456 adults with ADHD who successfully completed the study.
Attention Improvements
Totality of evidence demonstrated clinical benefit in attention. Average attention functioning improved by 1.1 points — measured using the TOVA®, a validated measure of attention.
Superior Clinical Improvement
In a global measure of clinical improvement (CGI-I), assessed by blinded clinicians, there was superior clinical benefit for LumosityRx users compared to a control group.
Improved Quality of Life
Participants demonstrated a clinically meaningful mean improvement in their quality of life — 8.7 points on the Adult ADHD Quality of Life Questionnaire [AAQoL].
Designed to Improve Your Attention
LumosityRx delivers 13 cognitive exercises that train attention, working memory, and cognitive control. Built on neuroscience, optimized for clinical use.
Engaging Game-Based Experience
MOTIVATING AND IMMERSIVE
Personalized Daily Regimen
~15 MINUTES/DAY, ADAPTS TO PROGRESS
In-App Feedback
TRACK IMPROVEMENTS AND HABITS
Frequently Asked Questions
Everything you need to know about LumosityRx
LumosityRx is software-as-a-medical device (SaMD) that runs on your mobile device and can be used at home. LumosityRx is a prescription digital therapeutic indicated to improve attention function in patients ages 22–55 with primarily inattentive or combined type ADHD. Patients who engage with LumosityRx demonstrate improvements in attention functioning and may not display benefits in other behavioral symptoms such as hyperactivity. LumosityRx is intended to be used as part of a therapeutic program that may include clinician-directed therapy, medication, and/or educational programs, which further address symptoms of the disorder. Individual results may vary.
A prescription digital therapeutic (PDT) is a software-based intervention that delivers medical treatment directly to patients. Unlike general health apps, PDTs are clinically validated, FDA-cleared, and require a prescription from a healthcare provider.
In a clinical study, LumosityRx users reported no serious device-related adverse events. Only 2 users (0.7%) reports of frustration that resolved with conclusion of gameplay. Always consult your healthcare provider about personalized medical advice.
LumosityRx is a prescription digital therapeutic indicated to improve attention function in adults ages 22-55 years old with primarily inattentive or combined-type Attention Deficit and Hyperactivity Disorder (ADHD).
LumosityRx is indicated for adults ages 22–55 with primarily inattentive or combined-type ADHD. It has not been evaluated in children or adolescents. It is available by prescription only, and a licensed clinician decides whether it is right for you. LumosityRx may not be appropriate for users with photo-sensitive epilepsy, color blindness, or physical limitations that restrict use of a mobile device.
LumosityRx is built on the same science-backed technology behind Lumosity but is specifically optimized, validated, and cleared for clinical use in adults with ADHD. While Lumosity is designed for general brain training, it is not intended to diagnose, treat, cure, or prevent any medical condition.
Everyone's needs are different — the best next step is to talk to your doctor about how LumosityRx might fit into your overall treatment plan.
Be the First to Access LumosityRx
We'll send you updates on our progress, including when LumosityRx is available.
Indications for Use
LumosityRx is the commercial name for Prismira, the device cleared by FDA under 510(k) K243729.
Limitations: LumosityRx may not be appropriate for users with photo-sensitive epilepsy, color blindness, or physical limitations that restrict use of a mobile device. Always consult with your healthcare provider before starting any new treatment. This information does not replace professional medical advice, diagnosis, or treatment.
© 2025 LumosityRx. All rights reserved. Prescription digital therapeutic. Consult your healthcare provider.